Akeso, Inc. (HKG: 9926)
Hong Kong
· Delayed Price · Currency is HKD 57.40
-1.95 (-3.29%)
Jan 7, 2025, 4:08 PM HKT
Akeso Revenue
Akeso had revenue of 1.02B CNY in the half year ending June 30, 2024, with 528.16% growth. This brings the company's revenue in the last twelve months to 1.87B, down -56.93% year-over-year. In the year 2023, Akeso had annual revenue of 4.53B with 440.35% growth.
Revenue (ttm)
1.87B CNY
Revenue Growth
-56.93%
P/S Ratio
23.98
Revenue / Employee
674.64K CNY
Employees
2,778
Market Cap
51.52B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 26.04B |
| Hansoh Pharmaceutical Group Company | 13.00B |
| JD Health International | 58.84B |
| WuXi Biologics | 18.39B |
| Sinopharm Group | 634.32B |
| Innovent Biologics | 8.01B |
| Sino Biopharmaceutical | 29.86B |
| CSPC Pharmaceutical Group | 33.53B |
Akeso News
- 2 months ago - BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga
- 2 months ago - Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Benzinga